Although some studies have shown that IDH mutations have no prognostic effect on OS in IDH-mutated (IDH1 and IDH2) patients or in overall patients,328–331IDH1 mutations have a poor prognosis impact on low-risk or intermediate -risk subgroups of patients with normal karyotype AML.328,331,333 In AML patients under 60 years old in the low-risk group, 5-year DFS (42% vs. 59%) and OS rates (50% vs. 63%) of IDH-mutated patients were significantly lower than those in IDH wild-type patients. This evidence concerns the gene IDH1 and acute myeloid leukemia.